| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Takahiro Kato, Yoshito Mizoguchi, Akira Monji, Hideki Horikawa, Satoshi O Suzuki, Yoshihiro Seki, Toru Iwaki, Sadayuki Hashioka, Shigenobu Kanb. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. Journal of neurochemistry. vol 106. issue 2. 2008-09-16. PMID:18429930. |
our results demonstrated that not only antipsychotics which have dopamine d(2) receptor antagonism but also aripiprazole have anti-inflammatory effects via the inhibition of microglial activation. |
2008-09-16 |
2023-08-12 |
Not clear |
| Katsuya Suemaru, Shuntaro Kohnomi, Kenta Umeda, Hiroaki Arak. [Evaluation of antipsychotic and relative drugs using disruption of prepulse inhibition as an animal model for schizophrenia]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 28. issue 3. 2008-09-11. PMID:18646597. |
in rodents, ppi can be disrupted by methamphetamine or phencyclidine, which causes psychotomimetic symptoms, and the dopaminergic agonist-induced ppi is reversed by dopamine d2 receptor antagonists and a dopaminergic partial agonist aripiprazole. |
2008-09-11 |
2023-08-12 |
mouse |
| Gerhard Gründer, Christine Fellows, Hildegard Janouschek, Tanja Veselinovic, Christian Boy, Anno Bröcheler, Katrin M Kirschbaum, Sandra Hellmann, Katja M Spreckelmeyer, Christoph Hiemke, Frank Rösch, Wolfgang M Schaefer, Ingo Vernaleke. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. The American journal of psychiatry. vol 165. issue 8. 2008-09-04. PMID:18381901. |
aripiprazole at clinically effective doses occupies some 90% of striatal dopamine 2 and 3 (d(2)/d(3)) receptors. |
2008-09-04 |
2023-08-12 |
Not clear |
| Takashi Hamamura, Masafumi Kodama, Toshiki Harad. Intrinsic activity of aripiprazole is not 30% of dopamine, but only about 6% under ideal antipsychotic therapy. The Journal of clinical psychiatry. vol 69. issue 5. 2008-09-03. PMID:18681765. |
intrinsic activity of aripiprazole is not 30% of dopamine, but only about 6% under ideal antipsychotic therapy. |
2008-09-03 |
2023-08-12 |
Not clear |
| Chi-Un Pae, Alessandro Serretti, Ashwin A Patkar, Praksh S Masan. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS drugs. vol 22. issue 5. 2008-08-01. PMID:18399707. |
aripiprazole also acts as a dopamine d2 partial receptor agonist, and has a possible action at adrenergic receptors. |
2008-08-01 |
2023-08-12 |
Not clear |
| Shuntaro Kohnomi, Katsuya Suemaru, Hiromu Kawasaki, Hiroaki Arak. Effect of aripiprazole on 5-HT2 receptor-mediated wet-dog shake responses and disruption of prepulse inhibition in rats. Journal of pharmacological sciences. vol 106. issue 4. 2008-07-24. PMID:18403899. |
the present study investigated the effects of aripiprazole on 5-ht(2a) receptor-mediated behaviors and compared them with the effects on dopamine receptor-mediated behavior in rats. |
2008-07-24 |
2023-08-12 |
rat |
| S D Iñiguez, A M Cortez, C A Crawford, S A McDougal. Effects of aripiprazole and terguride on dopamine synthesis in the dorsal striatum and medial prefrontal cortex of preweanling rats. Journal of neural transmission (Vienna, Austria : 1996). vol 115. issue 1. 2008-05-20. PMID:17994191. |
effects of aripiprazole and terguride on dopamine synthesis in the dorsal striatum and medial prefrontal cortex of preweanling rats. |
2008-05-20 |
2023-08-12 |
rat |
| R E Nordquist, C Risterucci, J L Moreau, M von Kienlin, B Künnecke, M Maco, C Freichel, C Riemer, W Spoore. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology. vol 54. issue 2. 2008-05-12. PMID:18054053. |
aripiprazole (opc-14597) is an antipsychotic with a unique pharmacology as a dopamine d2 receptor partial agonist, which has been demonstrated to reduce symptoms of schizophrenia. |
2008-05-12 |
2023-08-12 |
rat |
| Min-Chih Cheng, Ding-Lieh Liao, Chao A Hsiung, Chih-Yu Chen, Yu-Chieh Liao, Chia-Hsiang Che. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. The international journal of neuropsychopharmacology. vol 11. issue 2. 2008-05-08. PMID:17868501. |
aripiprazole is the first approved antipsychotic drug of the class of dopamine d2 receptor partial agonist, which has been shown to have similar efficacy and favourable side-effects profile compared to other antipsychotic drugs. |
2008-05-08 |
2023-08-12 |
rat |
| Juliana V Leite, Francisco S Guimarães, Fabricio A Moreir. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. European journal of pharmacology. vol 578. issue 2-3. 2008-04-03. PMID:18021764. |
aripiprazole is an atypical antipsychotic that acts as a partial agonist at the dopamine d(2) receptor. |
2008-04-03 |
2023-08-12 |
mouse |
| Euitae Kim, Jun Soo Kwon, Yong-Wook Shin, Jae Sung Lee, Won Jun Kang, Hang Joon Jo, Jong-Min Lee, Kyung-Sang Yu, Do-Hyung Kang, Joo-Youn Cho, In-Jin Jang, Sang-Goo Shi. Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. Pharmacogenetics and genomics. vol 18. issue 2. 2008-04-01. PMID:18192895. |
taq1a polymorphism in the dopamine d2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. |
2008-04-01 |
2023-08-12 |
human |
| C Tomasetti, C Dell'Aversano, F Iasevoli, A de Bartolomei. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience. vol 150. issue 1. 2008-03-28. PMID:17916411. |
animals were treated with the typical antipsychotic haloperidol 0.8 mg/kg, the atypical antipsychotic clozapine 15 mg/kg, the dopamine partial agonist aripiprazole 12 mg/kg and 30 mg/kg and the dopamine transporter inhibitor gbr12909 30 mg/kg in acute and chronic paradigms. |
2008-03-28 |
2023-08-12 |
rat |
| Yoshihiro Tadori, Hisashi Kitagawa, Robert A Forbes, Robert D McQuade, Arlene Stark, Tetsuro Kikuch. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. European journal of pharmacology. vol 574. issue 2-3. 2008-01-17. PMID:17692841. |
differences in agonist/antagonist properties at human dopamine d(2) receptors between aripiprazole, bifeprunox and sdz 208-912. |
2008-01-17 |
2023-08-12 |
human |
| Yoshihiro Tadori, Hisashi Kitagawa, Robert A Forbes, Robert D McQuade, Arlene Stark, Tetsuro Kikuch. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. European journal of pharmacology. vol 574. issue 2-3. 2008-01-17. PMID:17692841. |
aripiprazole is the first dopamine d(2) receptor partial agonist approved for use in schizophrenia and bipolar disorder. |
2008-01-17 |
2023-08-12 |
human |
| Mitsuru Shiokawa, Minoru Narita, Atsushi Nakamura, Kazuhiro Kurokawa, Tadao Inoue, Tsutomu Suzuk. Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis. European journal of pharmacology. vol 570. issue 1-3. 2007-11-30. PMID:17678644. |
usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis. |
2007-11-30 |
2023-08-12 |
Not clear |
| Mitsuru Shiokawa, Minoru Narita, Atsushi Nakamura, Kazuhiro Kurokawa, Tadao Inoue, Tsutomu Suzuk. Usefulness of the dopamine system-stabilizer aripiprazole for reducing morphine-induced emesis. European journal of pharmacology. vol 570. issue 1-3. 2007-11-30. PMID:17678644. |
in the present study, we investigated the effect of the dopamine system-stabilizer aripiprazole on morphine-induced emesis. |
2007-11-30 |
2023-08-12 |
Not clear |
| Liesbeth A Bruins Slot, Christiane Palmier, Stéphanie Tardif, Didier Cussa. Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation. Neuropharmacology. vol 53. issue 2. 2007-11-28. PMID:17588617. |
among the new generation dopamine d(2)/serotonin 5-ht(1a) antipsychotics, only f 15063 and slv313 acted as pure dopamine d(3) receptor antagonists, bifeprunox was highly efficacious whereas ssr181507 and aripiprazole showed marked partial agonist properties for erk 1/2 phosphorylation. |
2007-11-28 |
2023-08-12 |
human |
| Sunmee Wee, Zhixia Wang, William L Woolverton, Luigi Pulvirenti, George F Koo. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17327886. |
effect of aripiprazole, a partial dopamine d2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. |
2007-11-20 |
2023-08-12 |
rat |
| Sunmee Wee, Zhixia Wang, William L Woolverton, Luigi Pulvirenti, George F Koo. Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17327886. |
aripiprazole is a dopamine (da) d(2) receptor partial agonist, approved by the food and drug administration (fda) for the treatment of schizophrenia. |
2007-11-20 |
2023-08-12 |
rat |
| Jessica W Lea, Steven C Stoner, Jeremy Lafollett. Agitation associated with aripiprazole initiation. Pharmacotherapy. vol 27. issue 9. 2007-11-06. PMID:17723088. |
the mechanism of partial dopamine agonism observed with aripiprazole may increase dopaminergic activity and worsen positive dopamine-associated symptoms, such as paranoia, agitation, and aggression. |
2007-11-06 |
2023-08-12 |
Not clear |